pharmaphorum
MAY 9, 2022
SparkRx is designed to decrease depression in individuals aged 13 to 22 by providing a multi-week programme based on cognitive behavioural therapy (CBT) and behavioural activation protocols. “In In primary care, there are guidelines to screening for behavioural health concerns like depression annually. Designing the app.
pharmaphorum
DECEMBER 22, 2021
The 2022 intake companies are: Carium , which operates a telehealth platform – delivered via a patient app – that provides individualised care to patients from participating healthcare systems and links to a range of wearable devices; Clear Bill of Health (CBOH), which has developed as a COVID-19 vaccination and testing status facilitation tool; Culture (..)
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
APRIL 25, 2022
Aaron Gani, founder and CEO of BehaVR, and Krys Zaluski, director of business development, digital health at Sumitomo Dainippon Pharma, discuss their groundbreaking partnership to develop and commercialise digital therapeutics (DTx) products. . Gani started BehaVR in 2016 to create DTx for mental and behavioural health.
pharmaphorum
JANUARY 27, 2022
I observed that my colleagues who were working to develop and validate various clinical applications of virtual reality technology had no venue to publish their work in a way that would reach other scientists grappling with the same issues and constraints,” Greenleaf said. . To learn more about the IVRHA conference, click here.
pharmaphorum
JANUARY 26, 2021
There is an opportunity to address this at scale with digital tools and techniques, and expand support into just about any therapeutic area through the holistic integration of mental and behavioural health solutions that improve patient care. Services to manage and make sense of the health data explosion.
pharmaphorum
MARCH 21, 2022
In 2021, the behavioural health company and Sumitomo Dainippon Pharma Co. in Japan announced their partnership to develop and commercialise prescription digital therapeutics and general wellness products to treat social anxiety disorder, generalised anxiety, and major depressive disorder. About the author .
Drug Discovery World
JANUARY 12, 2023
DDW learnt more about this in an interview with Mark Matson, Senior Solution Specialist for Sensor Cloud at Medidata, focussing on how the use of digital biomarkers in life sciences and how they can help advance our understanding of disease. Clinic+, to understand the impact of the war and how the industry has been able to rebuild. .
Expert insights. Personalized for you.
128 
Let's personalize your content